Amphastar Pharmaceuticals, Inc. (AMPH) stock
AMPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 8/3013% below fair value
$29.10−0.07 (-0.24%)
Close on Nov 17, 2026Market cap $1.24BP/E 17.1Yield –
Amphastar Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Amphastar Pharmaceuticals's revenue for the twelve months ending Jun 30, 2026 was $730.02M, up 1.0% year over year. For fiscal 2025 it was $719.89M, down 1.7% from the year before. Over ten years it grew 11.1% a year on average. The highest annual figure on record is $731.97M in fiscal 2024.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $719.89M | -1.7% |
| FY2024 | Dec 31, 2024 | $731.97M | +13.6% |
| FY2023 | Dec 31, 2023 | $644.40M | +29.1% |
| FY2022 | Dec 31, 2022 | $498.99M | +14.0% |
| FY2021 | Dec 31, 2021 | $437.77M | +25.1% |
| FY2020 | Dec 31, 2020 | $349.85M | +8.5% |
| FY2019 | Dec 31, 2019 | $322.36M | +9.4% |
| FY2018 | Dec 31, 2018 | $294.67M | +22.7% |
| FY2017 | Dec 31, 2017 | $240.18M | -5.9% |
| FY2016 | Dec 31, 2016 | $255.17M | +1.4% |
| FY2015 | Dec 31, 2015 | $251.52M | +19.5% |
| FY2014 | Dec 31, 2014 | $210.46M | -8.4% |
| FY2013 | Dec 31, 2013 | $229.68M | +12.4% |
| FY2012 | Dec 31, 2012 | $204.32M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $183.90M | +5.4% |
| Q1 FY2026 | Mar 31, 2026 | $171.17M | +0.4% |
| Q4 FY2025 | Dec 31, 2025 | $183.11M | -1.8% |
| Q3 FY2025 | Sep 30, 2025 | $191.84M | +0.3% |
| Q2 FY2025 | Jun 30, 2025 | $174.41M | -4.4% |
| Q1 FY2025 | Mar 31, 2025 | $170.53M | -0.8% |
| Q4 FY2024 | Dec 31, 2024 | $186.52M | +4.7% |
| Q3 FY2024 | Sep 30, 2024 | $191.21M | +5.9% |
| Q2 FY2024 | Jun 30, 2024 | $182.39M | +25.2% |
| Q1 FY2024 | Mar 31, 2024 | $171.84M | +22.7% |
| Q4 FY2023 | Dec 31, 2023 | $178.11M | +31.9% |
| Q3 FY2023 | Sep 30, 2023 | $180.56M | +50.3% |
| Q2 FY2023 | Jun 30, 2023 | $145.71M | +18.0% |
| Q1 FY2023 | Mar 31, 2023 | $140.02M | +16.3% |
| Q4 FY2022 | Dec 31, 2022 | $135.02M | +11.7% |
| Q3 FY2022 | Sep 30, 2022 | $120.13M | +7.1% |
| Q2 FY2022 | Jun 30, 2022 | $123.47M | +21.4% |
| Q1 FY2022 | Mar 31, 2022 | $120.37M | +16.8% |
| Q4 FY2021 | Dec 31, 2021 | $120.89M | +26.0% |
| Q3 FY2021 | Sep 30, 2021 | $112.20M | +34.5% |
| Q2 FY2021 | Jun 30, 2021 | $101.66M | +18.5% |
| Q1 FY2021 | Mar 31, 2021 | $103.02M | +21.6% |
| Q4 FY2020 | Dec 31, 2020 | $95.92M | +15.0% |
| Q3 FY2020 | Sep 30, 2020 | $83.43M | +4.1% |
| Q2 FY2020 | Jun 30, 2020 | $85.81M | +8.6% |
| Q1 FY2020 | Mar 31, 2020 | $84.69M | +6.1% |
| Q4 FY2019 | Dec 31, 2019 | $83.38M | -7.0% |
| Q3 FY2019 | Sep 30, 2019 | $80.14M | +6.1% |
| Q2 FY2019 | Jun 30, 2019 | $79.05M | +11.3% |
| Q1 FY2019 | Mar 31, 2019 | $79.79M | +36.6% |
| Q4 FY2018 | Dec 31, 2018 | $89.69M | +48.5% |
| Q3 FY2018 | Sep 30, 2018 | $75.54M | +30.4% |
| Q2 FY2018 | Jun 30, 2018 | $71.04M | +9.0% |
| Q1 FY2018 | Mar 31, 2018 | $58.39M | +3.0% |
| Q4 FY2017 | Dec 31, 2017 | $60.40M | -4.9% |
| Q3 FY2017 | Sep 30, 2017 | $57.92M | -9.8% |
| Q2 FY2017 | Jun 30, 2017 | $65.19M | – |
| Q1 FY2017 | Mar 31, 2017 | $56.67M | – |
| Q4 FY2016 | Dec 31, 2016 | $63.54M | – |
| Q3 FY2016 | Sep 30, 2016 | $64.22M | – |
See a number that looks wrong?